Ignite Creation Date:
2024-05-06 @ 1:35 AM
Last Modification Date:
2024-10-26 @ 11:06 AM
Study NCT ID:
NCT01840046
Status:
TERMINATED
Last Update Posted:
2022-08-31
First Post:
2013-04-23
Brief Title:
Evaluation of the Efficacy and Tolerability of Treatment With Interleukin-2 in Severe and Resistant Alopecia Areata
Sponsor:
Centre Hospitalier Universitaire de Nice
Organization:
Centre Hospitalier Universitaire de Nice
Study Overview
Official Title:
Evaluation of the Efficacy and Tolerability of Treatment With Interleukin-2 in Severe Alopecia Areata Resistant to Conventional Systemic Treatment
Status:
TERMINATED
Status Verified Date:
2013-03
Last Known Status:
None
Delayed Posting:
No
If Stopped, Why?:
Not Stopped
Has Expanded Access:
False
If Expanded Access, NCT#:
N/A
Has Expanded Access, NCT# Status:
N/A
Acronym:
IL2
Brief Summary:
Alopecia areata is an autoimmune disease associated with infiltration of cluster of differentiation 4CD4 and cluster of differentiation 8 CD8 cells around the hair follicles One of the therapeutic approaches of inflammatory diseases such as alopecia areata is the induction of tolerance This tolerance induction can be obtained by stimulating regulatory T cells Treg The low-dose interleukin-2 plays a central role in the development expansion regulation and survival of regulatory T cells CD4 cluster of differentiation 25 CD25 forkhead box protein 3 FoxP3 Recently recombinant interleukin 2 IL2-R with low dose showed very promising results in two inflammatory disease GVHD vasculitis and cryoglobulinemia secondary to hepatitis C clinical efficacy increased population Treg in the blood and an excellent safety profile We hypothesized that administration of IL2-R in patients with severe alopecia areata might allow regrowth via activation of Treg and thus induce regrowth of the air
Detailed Description:
None
Study Oversight
Has Oversight DMC:
None
Is a FDA Regulated Drug?:
None
Is a FDA Regulated Device?:
None
Is an Unapproved Device?:
None
Is a PPSD?:
None
Is a US Export?:
None
Is an FDA AA801 Violation?:
None